CathWorks, a medical technology company based in Israel and California, announced that they received FDA clearance for the FFRangio System.

03 January 2019 Written by CN1699 Services Article viewed 6 times (0 times in the last week)

The FFRangio System is a non –invasive FFR platform, which precisely delivers multi-vessel physiological measurements to optimize intraprocuderal PCI therapy decisions.

For more details and uses visit CathWorks.

Image from CathWorks

Karen C

Off-Shore Manager - CN1699 Services